Masimo Corp is not a strong buy for a beginner, long-term investor at this moment. While the company has positive growth prospects and bullish analyst ratings, the recent financial performance, legal investigations, and overbought technical indicators suggest caution. Waiting for more clarity post-earnings and a better entry point is advisable.

Technical Analysis

The MACD is positive and contracting, indicating bullish momentum. The RSI is at 84.305, signaling overbought conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near resistance at R1: 175.031, with further resistance at R2: 186.05.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

The high Option Volume Put-Call Ratio indicates bearish sentiment in the options market, with more puts being traded than calls.

Technical Summary

Sell

Buy

Positive Catalysts

Analysts have raised price targets and are optimistic about the company's multi-year growth trajectory, driven by new products and innovation in MedTech. Revenue CAGR of 7%-10% through 2028 is expected.

Neutral/Negative Catalysts

The company is under investigation for potential securities law violations and fiduciary duty breaches. Financial performance in Q3 2025 showed a significant drop in net income (-1124.49% YoY) and EPS (-1133.33% YoY). RSI indicates overbought conditions, and the stock is trading near resistance levels.

Financial Performance

In Q3 2025, revenue increased by 8.21% YoY to $371.5 million, but net income dropped significantly to -$100.4 million (-1124.49% YoY), and EPS fell to -1.86 (-1133.33% YoY). Gross margin improved slightly to 62.07%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Wells Fargo and BTIG have raised price targets to $190 and $200, respectively, with Overweight and Buy ratings. Analysts are confident in the company's growth trajectory and innovation in MedTech.

6 Analyst Rating

Wall Street analysts forecast MASI stock price to rise

4 Buy

2 Hold

0 Sell

Moderate Buy

Current: 175.350

Low

162

Averages

188.4

High

210

Current: 175.350

Low

162

Averages

188.4

High

210

Wells Fargo

Overweight

maintain

$187 -> $190

AI Analysis

2025-12-05

Reason

Wells Fargo

Price Target

$187 -> $190

AI Analysis

2025-12-05

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on Masimo to $190 from $187 and keeps an Overweight rating on the shares. The firm says the company's Investor Day highlighted confidence in multi-year growth trajectory. Wells also notes that 7%-10% revenue CAGR through 2028, with new products is expected to drive double digits growth post-2028.

BTIG

Buy

maintain

$198 -> $200

2025-12-04

Reason

BTIG

Price Target

$198 -> $200

2025-12-04

maintain

Buy

Reason

BTIG raised the firm's price target on Masimo to $200 from $198 and keeps a Buy rating on the shares after the company's Investor Day presentation. The firm is positive on the company's potential to be one of the most consistent performers in MedTech over the coming years, the analyst tells investors in a research note. BTIG adds that it likes that the company will continue to invest in next-gen sensors and monitors in a market that has seen minimal product innovation from competitors and believes it will allow the company to achieve sustainable high single digit growth during and beyond the Long Range Plan.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MASI

Unlock Now

MASI Should I Buy

MASI Should I Buy

Should You Buy Masimo Corp (MASI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch